Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
The researchers tested whether a ctDNA-guided strategy could lower the need for adjuvant chemotherapy without increasing the risk of recurrence. Recurrence-free survival at 2 years was the main efficacy end objective. Adjuvant chemotherapy usage was a significant secondary end goal.
Oncology, Medical January 9th 2023
Clinical Advances in Hematology & Oncology
ctDNA provides an intriguing, noninvasive means of evaluating solid organ malignancies—from early diagnosis to personalized treatment decisions to prognosis and estimating risk of recurrence.
Oncology, Medical July 25th 2022
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH 